# Phase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma

Source: https://onco.cc/key-papers/paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019/  
OnCo record `paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In HER2-positive salivary duct carcinoma, an aggressive salivary cancer resembling breast cancer, trastuzumab plus docetaxel shrank tumours in 70 percent of patients, establishing HER2 testing and targeting in the disease.

## Summary

Single-arm phase 2 study of 57 patients with HER2-positive locally advanced, recurrent or metastatic salivary duct carcinoma treated with trastuzumab and docetaxel.

Objective response was 70.2 percent with a median progression-free survival of 8.9 months and median overall survival of 39.7 months, with toxicity similar to the regimen's use in breast cancer.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2019
- DOI: 10.1200/JCO.18.00545
- Authors: Takahashi H, Tada Y, Saotome T, et al.
- Findings: Objective response 70.2 percent.; Median progression-free survival 8.9 months; median overall survival 39.7 months.
- What it means: HER2 testing is standard in salivary duct carcinoma and trastuzumab-docetaxel a first-line option for HER2-positive advanced disease, with trastuzumab deruxtecan available at progression.
- Caveats: Single-arm study in a rare disease.; About 30 to 40 percent of salivary duct carcinomas are HER2-positive.

## Sources

- J Clin Oncol 2019: https://doi.org/10.1200/JCO.18.00545
- PubMed: https://pubmed.ncbi.nlm.nih.gov/30452336/

## Connected records

- cancers: [Salivary duct carcinoma](https://onco.cc/cancers/salivary-duct-carcinoma/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019.json